Popular Drugs To Lower Blood Pressure Increases The Risk Of Cancer.
Use of a average merit of drugs for high blood pressure and nerve failure is associated with a slight boost in cancer risk, a new review of data finds. The drugs are known as angiotensin-receptor blockers (ARBs) and count medicines such as telmisartan (Micardis), losartan (Cozaar, Hyzaar), valsartan (Diovan) and candesartan (Atacand). Overall, the researchers looked at trials involving over 223000 patients. When they concentrated on five trials involving over 60000 patients, in which cancer was a pre-specified endpoint, "patients assigned to these ARBs had about a 10 percent rise in cancer" germane to those not on the medications, said Dr Ilke Sipahi, aide professor of remedy at Case Western Reserve University, result in author of a report in the June 14 online copy of The Lancet Oncology.
The incidence of cancer in people taking an ARB was 7,2 percent, compared to a 6 percent degree in those taking a placebo, the analysis found. The increase in concrete tumors was concentrated in lung cancers, whose incidence was 25 percent higher in those taking an ARB. Despite the lifted in risk, the researchers noted that there was only a slight increase in deaths from cancer among ARB users - 1,8 percent for those taking ARBs, 1,6 percent for those taking placebo, a change that was not statistically significant.
Most of the masses in the trials - 85,7 percent - were taking the ARB telmisartan (Micardis), while the residuum took other ARBs such as losartan, valsartan and candesartan. The drugs work by blocking chamber receptors for angiotensin II, a hormone that plays an important role in regulating blood pressure. Another distinction of drugs that are used for the same purposes are the ACE inhibitors, which prevent the establishment of the active form of angiotensin. "Experimental studies using cancer cell lines and animal models have implicated the angiotensin procedure in the proliferation of cells and also tumors. Evidence from animal studies show that blockage of angiotensin receptors can inspirit tumor growth by promoting new blood vessel forming in tumors".
But the evidence that ARBs can play a real role in cancer growth remains unclear and these findings only show an association, not cause-and-effect. "Before we rift to that conclusion, I feel we need more analysis".
Showing posts with label cancer. Show all posts
Showing posts with label cancer. Show all posts
Tuesday 25 February 2020
Cancer Is One Of The Most Expensive Disease, And It Is Becoming More And More Expensive
Cancer Is One Of The Most Expensive Disease, And It Is Becoming More And More Expensive.
Millions of Americans with a recapitulation of cancer, uniquely common man under age 65, are delaying or skimping on medical care because of worries about the fetch of treatment, a new study suggests. The finding raises troubling questions about the long-term survival and mark of life of the 12 million adults in the United States whose lives have been forever changed by a diagnosis of cancer. "I mark it's concerning because we recognize that cancer survivors have many medical needs that linger for years after their diagnosis and treatment," said study lead inventor Kathryn E Weaver, an assistant professor in the Department of Social Sciences & Health Policy at Wake Forest University Baptist Medical Center in Winston-Salem, NC.
The explosion was published online June 14 in Cancer, a memoir of the American Cancer Society. Cost concerns have posed a risk to cancer survivorship for some time, particularly with the advent of new, life-prolonging treatments. Dr Patricia Ganz, a professor in the Department of Health Services at the University of California, Los Angeles School of Public Health, served on the Institute of Medicine commission that wrote the 2005 report, From Cancer Patient to Cancer Survivor: Lost in Transition. "One of the things that we in effect emphasized was shortage of insurance, strikingly for follow-up care".
CancerCare, a New York City-based nonprofit champion group for cancer patients, provides co-payment assistance for assured cancer medications. "Cancer is a vey expensive disease and it's becoming more and more expensive," said Jeanie M Barnett, CancerCare's maestro of communications. "The costs of the drugs are wealthy up. So, too, is the proportion that the patient pays out of pocket".
A March 17 commentary in the Journal of the American Medical Association, titled "Cancer's Next Frontier - Addressing High and Increasing Costs," reported that the unreflected costs of cancer had swelled from $27 billion in 1990 to more than $90 billion in 2008.
Millions of Americans with a recapitulation of cancer, uniquely common man under age 65, are delaying or skimping on medical care because of worries about the fetch of treatment, a new study suggests. The finding raises troubling questions about the long-term survival and mark of life of the 12 million adults in the United States whose lives have been forever changed by a diagnosis of cancer. "I mark it's concerning because we recognize that cancer survivors have many medical needs that linger for years after their diagnosis and treatment," said study lead inventor Kathryn E Weaver, an assistant professor in the Department of Social Sciences & Health Policy at Wake Forest University Baptist Medical Center in Winston-Salem, NC.
The explosion was published online June 14 in Cancer, a memoir of the American Cancer Society. Cost concerns have posed a risk to cancer survivorship for some time, particularly with the advent of new, life-prolonging treatments. Dr Patricia Ganz, a professor in the Department of Health Services at the University of California, Los Angeles School of Public Health, served on the Institute of Medicine commission that wrote the 2005 report, From Cancer Patient to Cancer Survivor: Lost in Transition. "One of the things that we in effect emphasized was shortage of insurance, strikingly for follow-up care".
CancerCare, a New York City-based nonprofit champion group for cancer patients, provides co-payment assistance for assured cancer medications. "Cancer is a vey expensive disease and it's becoming more and more expensive," said Jeanie M Barnett, CancerCare's maestro of communications. "The costs of the drugs are wealthy up. So, too, is the proportion that the patient pays out of pocket".
A March 17 commentary in the Journal of the American Medical Association, titled "Cancer's Next Frontier - Addressing High and Increasing Costs," reported that the unreflected costs of cancer had swelled from $27 billion in 1990 to more than $90 billion in 2008.
Tuesday 18 February 2020
Vaccination Of Young People Against HPV Will Reduce The Level Of Cancer
Vaccination Of Young People Against HPV Will Reduce The Level Of Cancer.
Although the low-down on the US cancer facing is generally good, experts discharge a troubling upswing in a few uncommon cancers linked to the sexually transmitted hominoid papillomavirus (HPV). Since 2000, certain cancers caused by HPV - anal cancer, cancer of the vulva, and some types of throat cancer - have been increasing, according to a strange set forth issued by federal health agencies in collaboration with the American Cancer Society. Overall, the report, published online Jan 7, 2013 in the Journal of the National Cancer Institute, finds fewer Americans sinking from joint cancers such as colon, breast and prostate cancers than in years past.
And the HPV-linked cancers are still rare. But experts maintain more could be done to prevent them - including boosting vaccination rates mid young people. "We have a vaccine that's acceptable and effective, and it's being used too little," said Dr Mark Schiffman, a senior investigator at the US National Cancer Institute.
More than 40 strains of HPV can be passed through procreant activity, and some of them can also upgrade cancer. The best known is cervical cancer. HPV is also blamed for most cases of anal cancer, a bountiful share of vaginal, vulvar and penile cancers, and some cases of throat cancer.
The uncharted report found that between 2000 and 2009, rates of anal cancer inched up among ashen and black men and women, while vulvar cancer rose among white and black women. HPV-linked throat cancers increased among white adults, even as smoking-related throat cancer became less common.
The reasons are not clear, said Edgar Simard, a major epidemiologist at the American Cancer Society who worked on the study. "HPV is a sexually transmitted virus, so we can wager that changes in fleshly practices may be involved". For example, prior studies have linked the rise in HPV-associated viva voce cancers to a rise in the popularity of oral sex.
HPV can be transmitted via oral intercourse, and a reading published in 2011 in the Journal of Clinical Oncology found that the percentage of oral cancers that are linked to HPV jumped from about 16 percent in the mid-1980s to 72 percent by 2004. Not all HPV-linked cancers have increased, and the biggest shut-out is cervical cancer. That cancer is almost always caused by HPV, but rates have been falling in the United States for years, and the drift continued after 2000.
That's because doctors routinely stop and criticize pre-cancerous abnormalities in the cervix by doing Pap tests and, in more recent years, tests for HPV. In compare there are no routine screening tests for the HPV-related cancers now on the rise. Those cancers do linger rare.
Although the low-down on the US cancer facing is generally good, experts discharge a troubling upswing in a few uncommon cancers linked to the sexually transmitted hominoid papillomavirus (HPV). Since 2000, certain cancers caused by HPV - anal cancer, cancer of the vulva, and some types of throat cancer - have been increasing, according to a strange set forth issued by federal health agencies in collaboration with the American Cancer Society. Overall, the report, published online Jan 7, 2013 in the Journal of the National Cancer Institute, finds fewer Americans sinking from joint cancers such as colon, breast and prostate cancers than in years past.
And the HPV-linked cancers are still rare. But experts maintain more could be done to prevent them - including boosting vaccination rates mid young people. "We have a vaccine that's acceptable and effective, and it's being used too little," said Dr Mark Schiffman, a senior investigator at the US National Cancer Institute.
More than 40 strains of HPV can be passed through procreant activity, and some of them can also upgrade cancer. The best known is cervical cancer. HPV is also blamed for most cases of anal cancer, a bountiful share of vaginal, vulvar and penile cancers, and some cases of throat cancer.
The uncharted report found that between 2000 and 2009, rates of anal cancer inched up among ashen and black men and women, while vulvar cancer rose among white and black women. HPV-linked throat cancers increased among white adults, even as smoking-related throat cancer became less common.
The reasons are not clear, said Edgar Simard, a major epidemiologist at the American Cancer Society who worked on the study. "HPV is a sexually transmitted virus, so we can wager that changes in fleshly practices may be involved". For example, prior studies have linked the rise in HPV-associated viva voce cancers to a rise in the popularity of oral sex.
HPV can be transmitted via oral intercourse, and a reading published in 2011 in the Journal of Clinical Oncology found that the percentage of oral cancers that are linked to HPV jumped from about 16 percent in the mid-1980s to 72 percent by 2004. Not all HPV-linked cancers have increased, and the biggest shut-out is cervical cancer. That cancer is almost always caused by HPV, but rates have been falling in the United States for years, and the drift continued after 2000.
That's because doctors routinely stop and criticize pre-cancerous abnormalities in the cervix by doing Pap tests and, in more recent years, tests for HPV. In compare there are no routine screening tests for the HPV-related cancers now on the rise. Those cancers do linger rare.
Physically Active People Are More Likely To Prevail Over Cancer
Physically Active People Are More Likely To Prevail Over Cancer.
People undergoing cancer healing traditionally have been told to dozing as much as possible and steer clear of exertion, to save all their strength to battle the dreaded disease. But a growing number of physicians and researchers now impart that people who remain physically active as best they can during treatment are more likely to beat cancer. The unambiguous evidence for exercise during and after cancer treatment has piled so high that an American College of Sports Medicine panel is revising the group's public guidelines regarding exercise recommended for cancer survivors.
The panel's conclusion: Cancer patients and survivors should contend to get the same amount of irritate recommended for everyone else, about 150 minutes a week of moderate-intensity aerobic exercise. Resistance training and stretching also are recommended.
People undergoing cancer healing traditionally have been told to dozing as much as possible and steer clear of exertion, to save all their strength to battle the dreaded disease. But a growing number of physicians and researchers now impart that people who remain physically active as best they can during treatment are more likely to beat cancer. The unambiguous evidence for exercise during and after cancer treatment has piled so high that an American College of Sports Medicine panel is revising the group's public guidelines regarding exercise recommended for cancer survivors.
The panel's conclusion: Cancer patients and survivors should contend to get the same amount of irritate recommended for everyone else, about 150 minutes a week of moderate-intensity aerobic exercise. Resistance training and stretching also are recommended.
Monday 17 February 2020
Weather Conditions May Affect Prostate Cancer Patients
Weather Conditions May Affect Prostate Cancer Patients.
A unique swotting links dry, cold weather to higher rates of prostate cancer. While the findings don't corroborate a direct link, researchers suspect that weather may affect adulteration and, in turn, boost prostate cancer rates. "We found that colder weather, and downcast rainfall, were strongly correlated with prostate cancer," researcher Sophie St-Hilaire, of Idaho State University, said in a scuttlebutt release.
So "Although we can't say exactly why this correlation exists, the trends are constant with what we would expect given the effects of climate on the deposition, absorption, and degradation of persistent systematic pollutants including pesticides". St-Hilaire and colleagues studied prostate cancer rates in counties in the United States and looked for links to state weather patterns.
They found a link, and suggest it may exist because polar weather slows the degradation of pollutants. Prostate cancer will strike about one in six men, according to CV information in the study. Reports suggest it's more common in the northern hemisphere.
A unique swotting links dry, cold weather to higher rates of prostate cancer. While the findings don't corroborate a direct link, researchers suspect that weather may affect adulteration and, in turn, boost prostate cancer rates. "We found that colder weather, and downcast rainfall, were strongly correlated with prostate cancer," researcher Sophie St-Hilaire, of Idaho State University, said in a scuttlebutt release.
So "Although we can't say exactly why this correlation exists, the trends are constant with what we would expect given the effects of climate on the deposition, absorption, and degradation of persistent systematic pollutants including pesticides". St-Hilaire and colleagues studied prostate cancer rates in counties in the United States and looked for links to state weather patterns.
They found a link, and suggest it may exist because polar weather slows the degradation of pollutants. Prostate cancer will strike about one in six men, according to CV information in the study. Reports suggest it's more common in the northern hemisphere.
Sunday 16 February 2020
Untreated Viral Hepatitis Leads To Liver Cancer
Untreated Viral Hepatitis Leads To Liver Cancer.
A ilk of liver cancer, hepatocellular carcinoma, is increasing in the United States, and fettle officials property much of the rise to untreated hepatitis infections. Chronic hepatitis B and hepatitis C are liable for 78 percent of hepatocellular carcinoma around the world. In the United States, as many as 5,3 million grass roots have chronic viral hepatitis and don't know it, according to the May 6 Morbidity and Mortality Weekly Report from the US Centers for Disease Control and Prevention (CDC).
So "The liver cancer rates are increasing in place against to most other foremost forms of cancer," said Dr John Ward, the man of CDC's viral hepatitis division and co-author of the report. Viral hepatitis is a outstanding reason for the increase.
The rate of hepatocellular carcinoma increased from 2,7 per 100,000 persons in 2001 to 3,2 in 2006 - an typical annual increase of 3,5 percent, according to the report. The highest rates are seen middle Asian Pacific Islanders and blacks, the CDC researchers noted.
This is of charge because opportunities exist for prevention. "There is a vaccine against hepatitis B that is routinely given to infants - so our children are protected, but adults, for the most part, are not". In addition, obedient treatments abide for both hepatitis B and C. "These will be even more effective in the days when new drugs currently in development come on the market".
A ilk of liver cancer, hepatocellular carcinoma, is increasing in the United States, and fettle officials property much of the rise to untreated hepatitis infections. Chronic hepatitis B and hepatitis C are liable for 78 percent of hepatocellular carcinoma around the world. In the United States, as many as 5,3 million grass roots have chronic viral hepatitis and don't know it, according to the May 6 Morbidity and Mortality Weekly Report from the US Centers for Disease Control and Prevention (CDC).
So "The liver cancer rates are increasing in place against to most other foremost forms of cancer," said Dr John Ward, the man of CDC's viral hepatitis division and co-author of the report. Viral hepatitis is a outstanding reason for the increase.
The rate of hepatocellular carcinoma increased from 2,7 per 100,000 persons in 2001 to 3,2 in 2006 - an typical annual increase of 3,5 percent, according to the report. The highest rates are seen middle Asian Pacific Islanders and blacks, the CDC researchers noted.
This is of charge because opportunities exist for prevention. "There is a vaccine against hepatitis B that is routinely given to infants - so our children are protected, but adults, for the most part, are not". In addition, obedient treatments abide for both hepatitis B and C. "These will be even more effective in the days when new drugs currently in development come on the market".
Beta Blockers May Also Help Lung Cancer Patients Live Longer
Beta Blockers May Also Help Lung Cancer Patients Live Longer.
New investigate suggests that beta blockers, medications that are employed to control blood put the screws on and heart rhythms, may also help lung cancer patients live longer. The researchers found that patients with non-small-cell lung cancer being treated with emission lived 22 percent longer if they were also taking these drugs. "These findings were the first, to our knowledge, demonstrating a survival advance associated with the use of beta blockers and diffusion therapy for lung cancer," said lead researcher Dr Daniel Gomez, an aide professor in the department of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston.
So "The results mean that there may be another mechanism, largely unexplored, that could potentially drop the rates of tumor spread in patients with this very aggressive disease". The story was published Jan 9, 2013 in the Annals of Oncology. For the study, Gomez's body compared the outcomes of more than 700 patients undergoing radiation therapy for lung cancer.
The investigators found that the 155 patients taking beta blockers for focus problems lived an average of almost two years, compared with an usual of 18,6 months for patients not taking these drugs. The findings held even after adjusting for other factors such as age, originate of the disease, whether or not chemotherapy was given at the same time, presence of chronic obstructive pulmonary infection and aspirin use, the researchers noted. Beta blockers also improved survival without the disease spreading to other parts of the body and survival without the disorder recurring.
New investigate suggests that beta blockers, medications that are employed to control blood put the screws on and heart rhythms, may also help lung cancer patients live longer. The researchers found that patients with non-small-cell lung cancer being treated with emission lived 22 percent longer if they were also taking these drugs. "These findings were the first, to our knowledge, demonstrating a survival advance associated with the use of beta blockers and diffusion therapy for lung cancer," said lead researcher Dr Daniel Gomez, an aide professor in the department of radiation oncology at the University of Texas MD Anderson Cancer Center in Houston.
So "The results mean that there may be another mechanism, largely unexplored, that could potentially drop the rates of tumor spread in patients with this very aggressive disease". The story was published Jan 9, 2013 in the Annals of Oncology. For the study, Gomez's body compared the outcomes of more than 700 patients undergoing radiation therapy for lung cancer.
The investigators found that the 155 patients taking beta blockers for focus problems lived an average of almost two years, compared with an usual of 18,6 months for patients not taking these drugs. The findings held even after adjusting for other factors such as age, originate of the disease, whether or not chemotherapy was given at the same time, presence of chronic obstructive pulmonary infection and aspirin use, the researchers noted. Beta blockers also improved survival without the disease spreading to other parts of the body and survival without the disorder recurring.
Scientists Have Discovered A New Method Of Detecting Cancer
Scientists Have Discovered A New Method Of Detecting Cancer.
A unexplored study marketed as an alternative to a mammogram for breast cancer detection is not an impressive screening TOOL, US health officials say. With the nipple aspirate test, a bust pump collects fluid from a woman's nipple. The fluid is then examined for eccentric and potentially cancerous cells. The test is advertised as easier, more comfortable and less painful than mammograms.
However, there is no ammunition to support claims that the test can detect breast cancer, said Dr David Lerner, a medical official at the US Food and Drug Administration and a breast imaging specialist. "FDA's trouble is that the nipple aspirate test is being touted as a standalone tool to screen for and distinguish breast cancer as an alternative to mammography," Lerner said in an agency news release.
So "Our horror is that women will forgo a mammogram and have this test instead". Skipping a mammogram could put a woman's constitution and life at risk if breast cancer goes undetected, Lerner warned. He said there is no detailed evidence that the nipple aspirate test, when used on its own, is an effective screening tool for knocker cancer or any other medical condition.
A unexplored study marketed as an alternative to a mammogram for breast cancer detection is not an impressive screening TOOL, US health officials say. With the nipple aspirate test, a bust pump collects fluid from a woman's nipple. The fluid is then examined for eccentric and potentially cancerous cells. The test is advertised as easier, more comfortable and less painful than mammograms.
However, there is no ammunition to support claims that the test can detect breast cancer, said Dr David Lerner, a medical official at the US Food and Drug Administration and a breast imaging specialist. "FDA's trouble is that the nipple aspirate test is being touted as a standalone tool to screen for and distinguish breast cancer as an alternative to mammography," Lerner said in an agency news release.
So "Our horror is that women will forgo a mammogram and have this test instead". Skipping a mammogram could put a woman's constitution and life at risk if breast cancer goes undetected, Lerner warned. He said there is no detailed evidence that the nipple aspirate test, when used on its own, is an effective screening tool for knocker cancer or any other medical condition.
Sunday 2 February 2020
Patients With Cancer Choose Surgery
Patients With Cancer Choose Surgery.
People with talk cancer who endure surgery before receiving radiation treatment fare better than those who start treatment with chemotherapy, according to a small reborn study. Many patients may be hesitant to begin their treatment with an invasive procedure, University of Michigan researchers noted. But advanced surgical techniques can pick up patients' chances for survival, the authors illustrious in a university news release. The study was published online Dec 26, 2013 in JAMA Otolaryngology Head and Neck Surgery.
Nearly 14000 Americans will be diagnosed with voice cancer this year and 2,070 will Euphemistic depart from the disease, according to the American Cancer Society. "To a minor person with tongue cancer, chemotherapy may sound like a better option than surgery with extensive reconstruction," inquiry author Dr Douglas Chepeha, a professor of otolaryngology-head and neck surgery at the University of Michigan Medical School, said in the despatch release. "But patients with oral pit cancer can't tolerate induction chemotherapy as well as they can handle surgery with follow-up radiation".
And "Our techniques of reconstruction are advanced and propose patients better survival and functional outcomes". The retreat involved 19 people with advanced oral cavity mouth cancer. All of the participants were given an first dose of chemotherapy (called "induction" chemotherapy). Patients whose cancer was reduced in square footage by 50 percent received more chemotherapy as well as radiation therapy.
People with talk cancer who endure surgery before receiving radiation treatment fare better than those who start treatment with chemotherapy, according to a small reborn study. Many patients may be hesitant to begin their treatment with an invasive procedure, University of Michigan researchers noted. But advanced surgical techniques can pick up patients' chances for survival, the authors illustrious in a university news release. The study was published online Dec 26, 2013 in JAMA Otolaryngology Head and Neck Surgery.
Nearly 14000 Americans will be diagnosed with voice cancer this year and 2,070 will Euphemistic depart from the disease, according to the American Cancer Society. "To a minor person with tongue cancer, chemotherapy may sound like a better option than surgery with extensive reconstruction," inquiry author Dr Douglas Chepeha, a professor of otolaryngology-head and neck surgery at the University of Michigan Medical School, said in the despatch release. "But patients with oral pit cancer can't tolerate induction chemotherapy as well as they can handle surgery with follow-up radiation".
And "Our techniques of reconstruction are advanced and propose patients better survival and functional outcomes". The retreat involved 19 people with advanced oral cavity mouth cancer. All of the participants were given an first dose of chemotherapy (called "induction" chemotherapy). Patients whose cancer was reduced in square footage by 50 percent received more chemotherapy as well as radiation therapy.
Wednesday 22 January 2020
Smoking And Weight Gain Increases The Death Rate From Prostate Cancer
Smoking And Weight Gain Increases The Death Rate From Prostate Cancer.
Men treated for prostate cancer who smoke or put on glut pounds amass their discrepancy of disease recurrence and of dying from the illness, two new studies show. The findings were presented Tuesday at the American Association for Cancer Research's annual conclave in Washington, DC.
In the fundamental report, a team led by Dr Jing Ma, an associate professor of pharmaceutical at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do augmentation the odds that a man who has the illness will die from it. Being overcast and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday matinal news conference.
"Compared to lean non-smokers, obese smokers had the highest jeopardy of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took role in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.
The researchers found that both avoirdupois move further and smoking boosted the risk for dying from the cancer. In fact, every five-point flourish in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a assessment of height versus weight, with the threshold of overweight set at a BMI of 25 and the sill for obesity set at a BMI of 30.
In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the muse about found. "These data underscore the lack for implementing effective preventive strategies for weight control and reducing tobacco use in both fit men as well as prostate cancer patients".
In a second report, a team led by Corinne E Joshu, a postdoctoral colleague in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained preponderance after having their prostate removed were almost twice as likely to discover their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR advice conference.
"Obesity, especially among serene men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's crew collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a examine on diet, lifestyle and other factors such as weight, zenith and physical activity five years before surgery and again one year after the procedure.
Men treated for prostate cancer who smoke or put on glut pounds amass their discrepancy of disease recurrence and of dying from the illness, two new studies show. The findings were presented Tuesday at the American Association for Cancer Research's annual conclave in Washington, DC.
In the fundamental report, a team led by Dr Jing Ma, an associate professor of pharmaceutical at Brigham and Women's Hospital in Boston, found that obesity and smoking may not be risk factors for developing prostate cancer, but they do augmentation the odds that a man who has the illness will die from it. Being overcast and smoking "predispose men to a significantly high risk of cancer-specific and all-cause mortality," Ma said during a Tuesday matinal news conference.
"Compared to lean non-smokers, obese smokers had the highest jeopardy of prostate cancer mortality". For the study, Ma's team collected data on more than 2700 men with prostate cancer who took role in the Physicians Health Study. Over 27 years of follow-up, 882 of the men died, 11 percent from the cancer.
The researchers found that both avoirdupois move further and smoking boosted the risk for dying from the cancer. In fact, every five-point flourish in body mass index (BMI) increased the risk for dying from prostate cancer by 52 percent. BMI is a assessment of height versus weight, with the threshold of overweight set at a BMI of 25 and the sill for obesity set at a BMI of 30.
In addition, men who smoked increased their risk for dying from the cancer by 55 percent, compared with men who never smoked, the muse about found. "These data underscore the lack for implementing effective preventive strategies for weight control and reducing tobacco use in both fit men as well as prostate cancer patients".
In a second report, a team led by Corinne E Joshu, a postdoctoral colleague in the department of epidemiology at Johns Hopkins Bloomberg School of Public Health, found that men who gained preponderance after having their prostate removed were almost twice as likely to discover their cancer return as were men who maintained their weight. "Weight gain may increase the risk of prostate cancer recurrence after prostatectomy," Joshu said during the AACR advice conference.
"Obesity, especially among serene men, may also contribute to the risk of prostate cancer recurrence". For the study, Joshu's crew collected data on more than 1300 men with localized prostate cancer who underwent prostatectomy between 1993 and 2006. In addition, the men completed a examine on diet, lifestyle and other factors such as weight, zenith and physical activity five years before surgery and again one year after the procedure.
Tuesday 7 January 2020
A Tan Is Still Admired By Ignoring The Danger Of Cancer
A Tan Is Still Admired By Ignoring The Danger Of Cancer.
Despite significant concerns about pellicle cancer, a the better of Americans nevertheless regard that having a tan is an attractive, desirable and healthy look, a new national survey finds. The enumerate was conducted by the American Academy of Dermatology (AAD) in January, and included just over 7100 men and women nationwide. "Our enquiry highlighted the contradictory feelings that many people have about tanning - they love the way a tan looks but are concerned about skin cancer, which is estimated to choose about one in five Americans in their lifetime," Dr Zoe D Draelos, a dermatologist and consulting professor at Duke University School of Medicine in Durham NC, said in a telecast release.
So "What they may not net is that no matter whether you tan or burn, a tan from the sun or tanning beds damages the peel and can cause wrinkles, age spots and skin cancer. The challenge is changing the long-standing attitudes about tanning to correlate with people's proficiency about skin cancer".
Despite significant concerns about pellicle cancer, a the better of Americans nevertheless regard that having a tan is an attractive, desirable and healthy look, a new national survey finds. The enumerate was conducted by the American Academy of Dermatology (AAD) in January, and included just over 7100 men and women nationwide. "Our enquiry highlighted the contradictory feelings that many people have about tanning - they love the way a tan looks but are concerned about skin cancer, which is estimated to choose about one in five Americans in their lifetime," Dr Zoe D Draelos, a dermatologist and consulting professor at Duke University School of Medicine in Durham NC, said in a telecast release.
So "What they may not net is that no matter whether you tan or burn, a tan from the sun or tanning beds damages the peel and can cause wrinkles, age spots and skin cancer. The challenge is changing the long-standing attitudes about tanning to correlate with people's proficiency about skin cancer".
Monday 6 January 2020
Physicians In The USA Recommend To Make A Mammography To All Women
Physicians In The USA Recommend To Make A Mammography To All Women.
More than three years after disputable recent guidelines rejected bit annual mammograms for most women, women in all age groups continue to get yearly screenings, a unusual survey shows. In fact, mammogram rates actually increased overall, from 51,9 percent in 2008 to 53,6 percent in 2011, even though the lightly made rise was not considered statistically significant, according to the researchers from Brigham and Women's Hospital and Harvard Medical School. "There have been no significant changes in the proportion of screening mammograms surrounded by any age group, but in particular among women under ripen 50," said the study leader, Dr Lydia Pace, a global women's fettle fellow in the division of women's health at Brigham and Women's.
While the study did not look at the reasons for continued screening, the researchers speculated that conflicting recommendations from various maestro organizations may play a role. In 2009, the US Preventive Services Task Force, an maverick panel of experts, issued unknown guidelines that said women younger than 50 don't need routine annual mammograms and those 50 to 74 could get screened every two years. Before that, the commendation was that all women elderly 40 and older get mammograms every one to two years.
The recommendations ignited much controversy and renewed dispute about whether delayed screening would increase breast cancer mortality. Since then, organizations such as the American Cancer Society have adhered to the recommendations that women 40 and older be screened annually. To undergo what object the new task force recommendations have had, the researchers analyzed facts from almost 28000 women over a six-year period - before and after the new task force guidelines.
The women were responding to the National Health Interview Survey in 2005, 2008 and 2011, and were asked how often they got a mammogram for screening purposes. Across the ages, there was no decay in screenings, the researchers found. Among women 40 to 49, the rates rose slightly, from 46,1 percent in 2008 to 47,5 percent in 2011. Among women old 50 to 74, the rates also rose, from 57,2 percent in 2008 to 59,1 percent in 2011.
More than three years after disputable recent guidelines rejected bit annual mammograms for most women, women in all age groups continue to get yearly screenings, a unusual survey shows. In fact, mammogram rates actually increased overall, from 51,9 percent in 2008 to 53,6 percent in 2011, even though the lightly made rise was not considered statistically significant, according to the researchers from Brigham and Women's Hospital and Harvard Medical School. "There have been no significant changes in the proportion of screening mammograms surrounded by any age group, but in particular among women under ripen 50," said the study leader, Dr Lydia Pace, a global women's fettle fellow in the division of women's health at Brigham and Women's.
While the study did not look at the reasons for continued screening, the researchers speculated that conflicting recommendations from various maestro organizations may play a role. In 2009, the US Preventive Services Task Force, an maverick panel of experts, issued unknown guidelines that said women younger than 50 don't need routine annual mammograms and those 50 to 74 could get screened every two years. Before that, the commendation was that all women elderly 40 and older get mammograms every one to two years.
The recommendations ignited much controversy and renewed dispute about whether delayed screening would increase breast cancer mortality. Since then, organizations such as the American Cancer Society have adhered to the recommendations that women 40 and older be screened annually. To undergo what object the new task force recommendations have had, the researchers analyzed facts from almost 28000 women over a six-year period - before and after the new task force guidelines.
The women were responding to the National Health Interview Survey in 2005, 2008 and 2011, and were asked how often they got a mammogram for screening purposes. Across the ages, there was no decay in screenings, the researchers found. Among women 40 to 49, the rates rose slightly, from 46,1 percent in 2008 to 47,5 percent in 2011. Among women old 50 to 74, the rates also rose, from 57,2 percent in 2008 to 59,1 percent in 2011.
Daily Long-Term Use Of Low-Dose Aspirin Reduces The Risk Of Death From Various Cancers
Daily Long-Term Use Of Low-Dose Aspirin Reduces The Risk Of Death From Various Cancers.
Long-term use of a ordinary low-dose aspirin dramatically cuts the danger of fading from a wide array of cancers, a new investigation reveals. Specifically, a British inspect team unearthed evidence that a low-dose aspirin (75 milligrams) captivated daily for at least five years brings about a 10 percent to 60 percent tear in fatalities depending on the type of cancer. The finding stems from a fresh analysis of eight studies involving more than 25,500 patients, which had from the outset been conducted to examine the protective potential of a low-dose aspirin regimen on cardiovascular disease.
The au courant observations follow prior research conducted by the same library team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the endanger of dying from colorectal cancer by a third. "These findings provide the first proof in mortals that aspirin reduces deaths due to several common cancers," the study team noted in a news release.
But the study's model author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that "these results do not undignified that all adults should immediately start taking aspirin. They do exhibit major new benefits that have not previously been factored into guideline recommendations," he added, noting that "previous guidelines have rightly cautioned that in tonic middle-aged people, the small risk of bleeding on aspirin partly offsets the promote from prevention of strokes and heart attacks".
And "But the reductions in deaths due to several banal cancers will now alter this balance for many people," Rothwell suggested. Rothwell and his colleagues published their findings Dec 7, 2010 in the online printing of The Lancet. The on involved in the current review had been conducted for an average period of four to eight years.
Long-term use of a ordinary low-dose aspirin dramatically cuts the danger of fading from a wide array of cancers, a new investigation reveals. Specifically, a British inspect team unearthed evidence that a low-dose aspirin (75 milligrams) captivated daily for at least five years brings about a 10 percent to 60 percent tear in fatalities depending on the type of cancer. The finding stems from a fresh analysis of eight studies involving more than 25,500 patients, which had from the outset been conducted to examine the protective potential of a low-dose aspirin regimen on cardiovascular disease.
The au courant observations follow prior research conducted by the same library team, which reported in October that a long-term regimen of low-dose aspirin appears to shave the endanger of dying from colorectal cancer by a third. "These findings provide the first proof in mortals that aspirin reduces deaths due to several common cancers," the study team noted in a news release.
But the study's model author, Prof. Peter Rothwell from John Radcliffe Hospital and the University of Oxford, stressed that "these results do not undignified that all adults should immediately start taking aspirin. They do exhibit major new benefits that have not previously been factored into guideline recommendations," he added, noting that "previous guidelines have rightly cautioned that in tonic middle-aged people, the small risk of bleeding on aspirin partly offsets the promote from prevention of strokes and heart attacks".
And "But the reductions in deaths due to several banal cancers will now alter this balance for many people," Rothwell suggested. Rothwell and his colleagues published their findings Dec 7, 2010 in the online printing of The Lancet. The on involved in the current review had been conducted for an average period of four to eight years.
Sunday 5 January 2020
A Promising Way To Treat Specific Lymphoma
A Promising Way To Treat Specific Lymphoma.
Researchers have identified a gene transmutation that may offering a target for new treatments for a type of lymphoma. The set found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as weighty B cell lymphoma. The MYD88 gene encodes a protein that is crucial for routine immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of virulent cells. A subgroup of the large B cell lymphoma that has a dismally crude cure rate - known as the activated B cell-like (ABC) subtype - appears especially susceptible to the gene.
Researchers have identified a gene transmutation that may offering a target for new treatments for a type of lymphoma. The set found that a mutation of the MYD88 gene is one of the most frequent genetic abnormalities in patients with this cancer, known as weighty B cell lymphoma. The MYD88 gene encodes a protein that is crucial for routine immune response to invading microorganisms.
The mutation identified in this study can cause uncontrolled cellular signaling, resulting in the survival of virulent cells. A subgroup of the large B cell lymphoma that has a dismally crude cure rate - known as the activated B cell-like (ABC) subtype - appears especially susceptible to the gene.
Saturday 4 January 2020
Prolonged Use Of Statins Does Not Increase The Risk Of Cancer
Prolonged Use Of Statins Does Not Increase The Risk Of Cancer.
New explore supports the general idea that patients who take cholesterol-lowering drugs known as statins may not have an increased hazard for cancer, as some previous studies suggested. Statins are the most commonly prescribed drugs for kith and kin with high blood cholesterol levels, which are linked to heart disease. Brand names number Crestor, Lipitor and Zocor. "Three or four years ago there was a broadening of articles pointing out that statins could produce cancer, and, at present, the most recent studies do not show this, and this is one of them," said Dr Valentin Fuster, by president of the American Heart Association and president of Mount Sinai Heart in New York City.
This latest study, slated for show Wednesday at the annual meeting of the American Heart Association in Chicago, was conducted by researchers from S2 Statistical Solutions, Inc, a ensemble that does economic research for health care-related businesses; the University of California, San Diego; and GE Healthcare, a allotment of General Electric, which provided the database for the study. Another just out study, reported Nov 10, 2010 at a assembly of the American Association for Cancer Research, also found that long-term use of statins did not increase the risk of cancer and might even dwindle users' risks for lymphoma, melanoma and endometrial tumors.
New explore supports the general idea that patients who take cholesterol-lowering drugs known as statins may not have an increased hazard for cancer, as some previous studies suggested. Statins are the most commonly prescribed drugs for kith and kin with high blood cholesterol levels, which are linked to heart disease. Brand names number Crestor, Lipitor and Zocor. "Three or four years ago there was a broadening of articles pointing out that statins could produce cancer, and, at present, the most recent studies do not show this, and this is one of them," said Dr Valentin Fuster, by president of the American Heart Association and president of Mount Sinai Heart in New York City.
This latest study, slated for show Wednesday at the annual meeting of the American Heart Association in Chicago, was conducted by researchers from S2 Statistical Solutions, Inc, a ensemble that does economic research for health care-related businesses; the University of California, San Diego; and GE Healthcare, a allotment of General Electric, which provided the database for the study. Another just out study, reported Nov 10, 2010 at a assembly of the American Association for Cancer Research, also found that long-term use of statins did not increase the risk of cancer and might even dwindle users' risks for lymphoma, melanoma and endometrial tumors.
Choice Of Place Of Death From Cancer
Choice Of Place Of Death From Cancer.
Doctors who would opt hospice anguish for themselves if they were dying from cancer are more likely to discuss such care with patients in that situation, a different study finds in Dec 2013. And while the majority of doctors in the study said they would essay hospice care if they were dying from cancer, less than one-third of those said they would discuss hospice care with terminally vile cancer patients at an early stage of care. Researchers surveyed nearly 4400 doctors who charge for cancer patients, including primary care physicians, surgeons, oncologists, dispersal oncologists and other specialists. They were asked if they would want hospice care if they were terminally ill with cancer.
They were also asked when they would examine hospice care with a patient with terminal cancer who had four to six months to persevere but had no symptoms: immediately; when symptoms first appear; when there are no more cancer treatment options; when the patient is admitted to hospital; or when the valetudinarian or family asks about hospice care. In terms of seeking hospice punctiliousness themselves, 65 percent of doctors were strongly in favor and 21 percent were less in favor.
Doctors who would opt hospice anguish for themselves if they were dying from cancer are more likely to discuss such care with patients in that situation, a different study finds in Dec 2013. And while the majority of doctors in the study said they would essay hospice care if they were dying from cancer, less than one-third of those said they would discuss hospice care with terminally vile cancer patients at an early stage of care. Researchers surveyed nearly 4400 doctors who charge for cancer patients, including primary care physicians, surgeons, oncologists, dispersal oncologists and other specialists. They were asked if they would want hospice care if they were terminally ill with cancer.
They were also asked when they would examine hospice care with a patient with terminal cancer who had four to six months to persevere but had no symptoms: immediately; when symptoms first appear; when there are no more cancer treatment options; when the patient is admitted to hospital; or when the valetudinarian or family asks about hospice care. In terms of seeking hospice punctiliousness themselves, 65 percent of doctors were strongly in favor and 21 percent were less in favor.
Wednesday 1 January 2020
Hispanic Men Are More Likely To Suffer From Polyps in Colon Than Women
Hispanic Men Are More Likely To Suffer From Polyps in Colon Than Women.
Among Hispanics, men are twice as right as women to have colon polyps and are also more appropriate to have multiple polyps, a restored study in Puerto Rico has found. The researchers also found that the scan patients older than 60 were 56 percent more likely to have polyps than those younger than 60. Polyps are growths in the stocky intestine. Some polyps may already be cancerous or can become cancerous.
The exploration included 647 patients aged 50 and older undergoing colorectal cancer screening at a gastroenterology clinic in Puerto Rico. In 70 percent of patients with polyps, the growths were on the dexter sect of the colon. In white patients, polyps are typically found on the left incidental of the colon. This difference may result from underlying molecular differences in the two patient groups, said examination author Dr Marcia Cruz-Correa, an associate professor of medicine and biochemistry at the University of Puerto Rico Cancer Center.
The decree about polyp location is important because it highlights the call to use colonoscopy when conducting colorectal cancer screening in Hispanics. This is the most effective pattern of detecting polyps on the right side of the colon. The study was to be presented Sunday at the Digestive Diseases Week meet in New Orleans.
Among Hispanics, men are twice as right as women to have colon polyps and are also more appropriate to have multiple polyps, a restored study in Puerto Rico has found. The researchers also found that the scan patients older than 60 were 56 percent more likely to have polyps than those younger than 60. Polyps are growths in the stocky intestine. Some polyps may already be cancerous or can become cancerous.
The exploration included 647 patients aged 50 and older undergoing colorectal cancer screening at a gastroenterology clinic in Puerto Rico. In 70 percent of patients with polyps, the growths were on the dexter sect of the colon. In white patients, polyps are typically found on the left incidental of the colon. This difference may result from underlying molecular differences in the two patient groups, said examination author Dr Marcia Cruz-Correa, an associate professor of medicine and biochemistry at the University of Puerto Rico Cancer Center.
The decree about polyp location is important because it highlights the call to use colonoscopy when conducting colorectal cancer screening in Hispanics. This is the most effective pattern of detecting polyps on the right side of the colon. The study was to be presented Sunday at the Digestive Diseases Week meet in New Orleans.
Sunday 29 December 2019
Addiction To Tanning Greatly Increases The Risk Of Skin Cancer
Addiction To Tanning Greatly Increases The Risk Of Skin Cancer.
People who use tanning beds to husband that year-round ruddiness are dramatically increasing their imperil for developing melanoma, the deadliest of skin cancers, a new study finds. In fact, the more you tan and the longer you tan, the more the gamble increases. "We found the risk of melanoma was 74 percent higher in persons who tanned indoors than in persons who had not," said suggestion researcher DeAnn Lazovich, an subsidiary professor at the division of epidemiology and community health at the University of Minnesota. "We also found that forebears who tanned indoors a lot were 2,5 to 3 times more likely to develop melanoma than population who had never tanned indoors".
In the context of the study, "a lot" of indoor tanning meant a aggregate of at least 50 hours of tanning bed exposure, or more than 100 sessions, or at least 10 years of pleasant tanning bed use. The report is published in the May 27 son of Cancer Epidemiology, Biomarkers & Prevention. For the study, Lazovich's body collected data on melanoma cases in Minnesota from 2004 through 2007. The researchers also conducted interviews and had patients uncut questionnaires about indoor tanning, including the devices used, when the individual began tanning and for how long.
The researchers found that among 1167 people with melanoma, almost two-thirds (63 percent) had reach-me-down tanning beds. Among those who used tanning beds, the risk for developing melanoma rose 74 percent, Lazovich's organize found. The risk for melanoma was significant whether the tanning beds employed both UVA and UVB rays or UVA rays only.
For beds using UVA rays, the jeopardy of melanoma was increased 4,4 - fold. "What is memorable about our results are that they are very consistent. We found these relationships whether we looked at it by age, by gender, by where the tumor was found or by how we measured how much tribe tanned or what kind of devices they used".
Lazovich noted that the danger is particularly acute among litter women who seem to have a predilection for indoor tanning. "Indoor tanning is an underappreciated problem, especially among babyish women. More young women tan indoors than smoke cigarettes, and melanoma is the subsequent most common cancer diagnosed in young women. And there is evidence that the incidence of melanoma is increasing in infantile women. It's time to pay a little more attention to this as a risk factor that is avoidable".
People who use tanning beds to husband that year-round ruddiness are dramatically increasing their imperil for developing melanoma, the deadliest of skin cancers, a new study finds. In fact, the more you tan and the longer you tan, the more the gamble increases. "We found the risk of melanoma was 74 percent higher in persons who tanned indoors than in persons who had not," said suggestion researcher DeAnn Lazovich, an subsidiary professor at the division of epidemiology and community health at the University of Minnesota. "We also found that forebears who tanned indoors a lot were 2,5 to 3 times more likely to develop melanoma than population who had never tanned indoors".
In the context of the study, "a lot" of indoor tanning meant a aggregate of at least 50 hours of tanning bed exposure, or more than 100 sessions, or at least 10 years of pleasant tanning bed use. The report is published in the May 27 son of Cancer Epidemiology, Biomarkers & Prevention. For the study, Lazovich's body collected data on melanoma cases in Minnesota from 2004 through 2007. The researchers also conducted interviews and had patients uncut questionnaires about indoor tanning, including the devices used, when the individual began tanning and for how long.
The researchers found that among 1167 people with melanoma, almost two-thirds (63 percent) had reach-me-down tanning beds. Among those who used tanning beds, the risk for developing melanoma rose 74 percent, Lazovich's organize found. The risk for melanoma was significant whether the tanning beds employed both UVA and UVB rays or UVA rays only.
For beds using UVA rays, the jeopardy of melanoma was increased 4,4 - fold. "What is memorable about our results are that they are very consistent. We found these relationships whether we looked at it by age, by gender, by where the tumor was found or by how we measured how much tribe tanned or what kind of devices they used".
Lazovich noted that the danger is particularly acute among litter women who seem to have a predilection for indoor tanning. "Indoor tanning is an underappreciated problem, especially among babyish women. More young women tan indoors than smoke cigarettes, and melanoma is the subsequent most common cancer diagnosed in young women. And there is evidence that the incidence of melanoma is increasing in infantile women. It's time to pay a little more attention to this as a risk factor that is avoidable".
Friday 27 December 2019
Smokers Get Sick Of Colorectal Cancer Earlier
Smokers Get Sick Of Colorectal Cancer Earlier.
A callow swat has uncovered a strong link between smoking and the development of precancerous polyps called non-reflective adenomas in the large intestine, a finding that researchers say may explain the earlier onset of colorectal cancer in the midst smokers. Flat adenomas are more aggressive and harder to spot than the raised polyps that are typically detectable during column colorectal screenings, the authors noted. This fact, coupled with their affiliation with smoking, could also explain why colorectal cancer is usually caught at a more advanced stage and at a younger maturity among smokers than nonsmokers.
So "Little is known regarding the risk factors for these boring lesions, which may account for over one-half of all adenomas detected with a high-definition colonoscope," study author Dr Joseph C Anderson, of the Neag Comprehensive Cancer Center at the University of Connecticut Health Center, said in a talk manumitting from the American Society for Gastrointestinal Endoscopy. But, "smoking has been shown to be an distinguished risk factor for colorectal neoplasia tumor formation in several screening studies".
A callow swat has uncovered a strong link between smoking and the development of precancerous polyps called non-reflective adenomas in the large intestine, a finding that researchers say may explain the earlier onset of colorectal cancer in the midst smokers. Flat adenomas are more aggressive and harder to spot than the raised polyps that are typically detectable during column colorectal screenings, the authors noted. This fact, coupled with their affiliation with smoking, could also explain why colorectal cancer is usually caught at a more advanced stage and at a younger maturity among smokers than nonsmokers.
So "Little is known regarding the risk factors for these boring lesions, which may account for over one-half of all adenomas detected with a high-definition colonoscope," study author Dr Joseph C Anderson, of the Neag Comprehensive Cancer Center at the University of Connecticut Health Center, said in a talk manumitting from the American Society for Gastrointestinal Endoscopy. But, "smoking has been shown to be an distinguished risk factor for colorectal neoplasia tumor formation in several screening studies".
Thursday 26 December 2019
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer
Omnitarg And Herceptin Could Save Women Without Chemotherapy From Breast Cancer.
Combinations of targeted therapies for an especially martial strain of breast cancer could potentially usher the best part of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to use HER2-positive tumors resulted in much higher forgiveness rates than doses of any one treat or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is quick to a protein called sympathetic epidermal expansion factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically quarry HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven efficacious on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very rousing era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of prescription at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with originally core cancer at 85 facilities throughout Germany. About half of these patients achieved deliverance before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer sphere of influence at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy".
The rig will continue following the patients to see if remission at surgery affects their outcome. Another cram showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Combinations of targeted therapies for an especially martial strain of breast cancer could potentially usher the best part of affected patients into remission, researchers at a major breast cancer meeting said Friday. Presenting results from three trials at the annual San Antonio Breast Cancer Symposium, scientists explained that administering two or more drugs designed to use HER2-positive tumors resulted in much higher forgiveness rates than doses of any one treat or standard chemotherapy alone. Given to patients several weeks before cancer surgery, with or without chemotherapy, the medications often shrank tumors dramatically or eradicated them altogether, the researchers said.
HER2-positive cancer is quick to a protein called sympathetic epidermal expansion factor receptor 2, which promotes the growth of malignant cells. Drugs that specifically quarry HER2 cells - including Herceptin, Tykerb and Omnitarg - have been proven efficacious on these types of tumors, which tend to be more aggressive than other breast cancers. "I think it's a very rousing era, because we've gone from a very lethal era - to a point where we might be able to cure this disease," said Dr Neil Spector, a professor of prescription at Duke University Medical Center, who moderated the symposium session.
Using Tykerb and Herceptin combined with chemotherapy before surgery, researchers followed 2,500 women with originally core cancer at 85 facilities throughout Germany. About half of these patients achieved deliverance before surgery, said Dr Michael Untch, head of the multidisciplinary breast cancer sphere of influence at Helios Clinic in Berlin. "In a majority of these patients, we could do breast-conserving surgery where previously they were candidates for mastectomy".
The rig will continue following the patients to see if remission at surgery affects their outcome. Another cram showed the combination of Omnitarg and Herceptin, when given with the chemotherapy drug docetaxel, eradicated 46 percent of tumors, 50 percent more than the results achieved without Omnitarg. Also, 17 percent of tumors were eradicated by combining the two targeted drugs and skipping chemotherapy, the researchers said.
Subscribe to:
Posts (Atom)